By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has entered into a licensing agreement with German pharmaceutical giant Merck KGaA (ETR: MRK) for its oral non-peptide GnRH receptor antagonist, SHR7280. This collaboration focuses on advancing SHR7280 in the field of assisted reproduction, with Merck securing exclusive commercialization rights in mainland China.
Drug Profile
SHR7280 is designed as an oral non-peptide GnRH receptor antagonist, offering advantages such as convenient administration and high patient compliance. It is positioned to become the first product of its kind in the global assisted reproductive field, addressing significant unmet medical needs.
Agreement Details
Under the terms of the agreement, Merck KGaA will receive exclusive commercialization rights to SHR7280 in mainland China. Hengrui Pharmaceuticals will receive an upfront payment of EUR 15 million (USD 16.5 million) and is eligible for milestone payments upon product approval, along with a double-digit percentage commission on net sales. This strategic partnership underscores Hengrui’s commitment to expanding its global footprint in reproductive health.-Fineline Info & Tech